Megan Arens, PA
Physician Assistant · Crofton, NENPI 1679961676
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.2%), travel and lodging and education — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Medtronic at 34.1% of the total. Reporting peaked in 2024 at $3,430 and has fallen 60.9% since, to $1,343 in 2025. Among physician assistant clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 213 payments — averaging $41.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Boston Scientific$2K
- Pacira Pharmaceuticals Incorporated$769
- AbbVie$612
- Amgen$280
- Collegium Pharmaceutical, Inc.$260
- plus $2K from 22 others
What the payments were for
- Travel & lodging$3,95545%
- Food & beverage$4,73454%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 45 | $2,976 |
| Boston Scientific | 13 | $2,182 |
| Pacira Pharmaceuticals Incorporated | 5 | $769 |
| AbbVie(2 entities) | 39 | $612 |
| Amgen(2 entities) | 16 | $280 |
| Collegium Pharmaceutical, Inc. | 8 | $260 |
| Biohaven Pharmaceuticals, Inc. | 13 | $207 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $176 |
| Lilly USA, LLC | 10 | $164 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $164 |
| Pfizer | 9 | $148 |
| Merck | 8 | $127 |
| GRT US Holding, Inc. | 4 | $123 |
| Arbor Pharmaceuticals, Inc. | 5 | $83 |
| Redhill Biopharma Inc. | 1 | $71 |
| Averitas Pharma Inc. | 2 | $68 |
| Lundbeck LLC | 4 | $57 |
| Forte Bio-pharma LLC | 2 | $42 |
| Idorsia Pharmaceuticals US Inc | 2 | $37 |
| Supernus Pharmaceuticals, Inc. | 3 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Vertex | 2 | $31 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| Indivior Inc. | 1 | $16 |
| Novo Nordisk | 1 | $14 |
| Nalu Medical, Inc. | 2 | $13 |
| IBSA Pharma Inc. | 1 | $13 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYNCHROMEDII$1,785
- Intracept$1,266
- Iovera$694
How this compares
$8,735 in reported general payments places this provider in the 95th percentile of 1,127 physician assistant providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 46 | $75,534 |
| QuliptaAtogepant | 41 | $54,509 |
| Nurtec OdtRimegepant Sulfate | 20 | $32,980 |
| Buprenorphine | 94 | $30,648 |
| OxycontinOxycodone Hcl | 32 | $25,890 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 101 | $21,069 |
| NucyntaTapentadol Hcl | 17 | $13,873 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 388 | $11,549 |
| Xtampza ErOxycodone Myristate | 18 | $10,570 |
| Pregabalin | 357 | $9,969 |
| Buprenorphine Hcl | 232 | $9,833 |
| BelbucaBuprenorphine Hcl | 11 | $8,427 |
| Emgality PenGalcanezumab-Gnlm | 11 | $7,383 |
| Oxymorphone Hcl ErOxymorphone Hcl | 11 | $5,529 |
| BelsomraSuvorexant | 11 | $4,859 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $612 | $130,04387 claims |
| PfizerNurtec Odt | $148 | $32,98020 claims |
| Collegium Pharmaceutical, Inc.Nucynta, Xtampza Er, Belbuca | $260 | $32,87046 claims |
| MerckBelsomra | $127 | $4,85911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,127 physician assistant providers in Nebraska.
Other physician assistant in Crofton
- Kimberly GatesOmaha$109K
- Kandice DoleshOmaha$106K
- Ronda FoleyElkhorn$64K
- Kathryn KestiOmaha$34K
- Sarah GretemanOmaha$24K
- Joel JasaGrand Island$18K
- Christopher BeasleyOmaha$15K
- Courtney MaresLincoln$13K
- Corrine GiggeeOmaha$12K
- Austin DuerksenOmaha$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.